

POSTER PRESENTATION

Open Access

# P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)

HM Specht<sup>1\*</sup>, J Pelzel<sup>1</sup>, H Hautmann<sup>2</sup>, RM Huber<sup>3</sup>, B Schossow<sup>4</sup>, M Molls<sup>1</sup>, G Multhoff<sup>1</sup>

From 1st Immunotherapy of Cancer Conference (ITOC1)  
Munich, Germany. 12-14 March 2014

Membrane-bound Hsp70 serves as a recognition structure for NK cells that were pre-stimulated with Hsp70 peptide TKD plus low dose IL-2 *in vitro* and in mouse models. In a clinical phase I trial feasibility, safety and tolerability of *ex vivo* TKD/IL-2 stimulated autologous NK cells has been demonstrated in patients with metastasised colorectal carcinoma and NSCLC. Based on these findings a proof-of-concept phase II randomised clinical trial was initiated (BMBF - Innovative therapies). NSCLC patients will be treated with *ex vivo* stimulated NK cells after RCT. Most patients are diagnosed in locally advanced disease stages IIIA and IIIB. After conventional radiochemotherapy only part of the patients (less than 50%) show remission and despite improvements in standard therapies the mortality associated with this disease is very high (5 year survival rate does not exceed 15%). Therefore there is a strong medical need for innovative treatment strategies. Since an Hsp70 membrane-positive tumour phenotype is associated with a poor clinical outcome, only Hsp70 membrane-positive tumour patients are recruited into the trial. Leukapheresis products are generated centralised and cell processing is performed in a GMP-laboratory.

The aim of the study is to show the efficacy of the treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard RCT by improvement of PFS.

#### Authors' details

<sup>1</sup>Klinikum rechts der Isar - Technische Universität München, Strahlentherapie und Radiologische Onkologie, Munich, Germany. <sup>2</sup>Klinikum rechts der Isar - Technische Universität München, I.Medizinische Klinik - Pneumologie, Munich, Germany. <sup>3</sup>Ludwig-Maximilians-Universität, Medizinische Klinik - Innenstadt - Pneumologie, Munich, Germany. <sup>4</sup>Klinikum rechts der Isar - Technische Universität München, MSZ - Münchner Studien Zentrum, Munich, Germany.

Published: 12 March 2014

doi:10.1186/2051-1426-2-S2-P41

**Cite this article as:** Specht et al.: P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70). *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 2):P41.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



<sup>1</sup>Klinikum rechts der Isar - Technische Universität München, Strahlentherapie und Radiologische Onkologie, Munich, Germany  
Full list of author information is available at the end of the article